Novavax (NASDAQ:NVAX) has yet to begin its anticipated U.S. late-stage study of its COVID-19 vaccine candidate. But if you're thinking that this puts Moderna and Novavax in completely different leagues, think again. Actually, there are three big advantages that Novavax has over Moderna.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,